We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Moleculin Biotech Inc
25 own
28 watching
Current Price
$4.31
$-0.04
(-0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
12.74M
52-Week High
6.24000
52-Week Low
0.33800
Average Volume
0.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization12.74M52-Week High6.2400052-Week Low0.33800Average Volume0.02MDividend Yield--P/E Ratio--What does the Moleculin Biotech Inc do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company s flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Read More
How much money does Moleculin Biotech Inc make?
News & Events about Moleculin Biotech Inc.
Zolmax
1 year ago
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock. Separately, Oppenheimer reiterated an outperform rating and set a $5.00 target price on shares of Moleculin Biotech in...
PR Newswire
1 year ago
Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High...
Ticker Report
1 year ago
StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a report issued on Saturday morning. The firm issued a sell rating on the stock. Moleculin Biotech Stock Performance NASDAQ MBRX opened at $0.94 on Friday. The company has a market capitalization of $26...
Zolmax
1 year ago
StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a report released on Tuesday. The firm issued a sell rating on the stock. Separately, Oppenheimer lowered their target price on Moleculin Biotech from $14.00 to $5.00 in a report on Friday, November 11th. ...
Frequently Asked Questions
Frequently Asked Questions
What is Moleculin Biotech Inc share price today?
Can Indians buy Moleculin Biotech Inc shares?
How can I buy Moleculin Biotech Inc shares from India?
Can Fractional shares of Moleculin Biotech Inc be purchased?
What are the documents required to start investing in Moleculin Biotech Inc stocks?
What is today’s traded volume of Moleculin Biotech Inc?
What is today’s market capitalisation of Moleculin Biotech Inc?
What is the 52-Week High and Low Range of Moleculin Biotech Inc?
What percentage is Moleculin Biotech Inc down from its 52-Week High?
What percentage is Moleculin Biotech Inc up from its 52-Week Low?
Current Price
$4.31
$-0.04
(-0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.